Wednesday, 28 September, 2022
TopicBharat Biotech

Topic: Bharat Biotech

Drug authority clears use of India’s first nasal Covid-19 vaccine made by Bharat Biotech

The Covaxin maker’s nasal shot will be used in emergency situations for the 18+ age group, Union Health Minister Mansukh Mandaviya tweeted.

WHO move to suspend Covaxin’s UN supply won’t affect trips to UK, US & over 90 nations, govt says

Bharat Biotech is believed to have assured Government of India that it will ‘quickly’ reply to WHO about ‘deficiencies found in its manufacturing’ during an inspection last month.

DCGI gives emergency use approval to Biological E’s Corbevax vaccine for kids aged 12-18

It is the second Covid vaccine to get approval for use in children in India after Bharat Biotech's Covaxin.

ICMR received Rs 171.74 cr in royalty from sale of Covaxin till 31 Jan, govt tells Rajya Sabha

ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.

Bharat Biotech gets DCGI’s nod to conduct ​clinical trials of intranasal Covid vaccine BBV154

The dosage form of the vaccine is liquid, containing 0.5ml/per dose for the intranasal route of administration. The trials will take place at nine different sites of the country.

Study shows Covaxin booster dose neutralises both Omicron, Delta variants: Bharat Biotech

Bharat Biotech said a study at Emory University demonstrated that people who got a Covaxin booster, 6 months after the two doses, witnessed neutralising of the two Covid variants.

Covaxin booster increases antibody levels by 19-97 fold against Covid variants: Phase 2 results

Study, which is yet to be peer-reviewed, was published on preprint portal medRxiv Saturday. It was conducted by Bharat Biotech and ICMR, which co-developed the vaccine.

Covaxin demonstrates robust safety and immunogenicity in 2-18-year-old volunteers, study says

The data was submitted to the Central Drugs Standard Control Organisation during October 2021 and received emergency use nod for children aged 12-18 from DCGI recently.

Covaxin was 50% effective among health workers in 2nd wave, real-world study from AIIMS shows

Study published in Lancet Infectious Diseases journal assessed 2,714 hospital workers from AIIMS New Delhi, who were most exposed to Covid and were primarily offered Covaxin.

Good news for kids: Expert panel gives Covaxin emergency approval for 2-18-year-olds

The phase 2/3 clinical trials for Covaxin for children were completed last month. The SEC will now send its recommendations to DCGI.

On Camera


The logo of the Adani Group is seen on the facade of one of its buildings on the outskirts of Ahmedabad | Reuters file photo

From ports to energy transition — Adani Group to invest over $100 billion in next decade

Speaking at Forbes Global CEO Conference in Singapore, Adani said the group intends to do more as a solar player & has earmarked 70% of the investment for the energy transition space.


Parts of Iranian made 'suicide' drone Shahed-136 after being shot down by the Ukrainian military | Reuters

All about Shahed-136, Iran’s ‘kamikaze’ drone that Russia is using to strike Ukraine

Over the past few days, Russia has hit multiple targets using these Iranian-supplied drones—including civilian structures and amenities—leading to the death of several Ukrainians.
Illustration by Soham Sen | ThePrint

AAP’s filling a big vacuum in Indian politics. Question is how long it can sustain without ideology

If you find admiration for AAP qualified, if not muted among many of the Modi-BJP’s critics, it is because they question it for its lack of ideological clarity. Especially on secularism.